---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Natural history, survival, and mortality"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Natural history, survival, and mortality. Topics: Five-year relative survival, all uveal melanoma, 1975 to 2016; Five-year and ten-year relative survival, all uveal melanoma; U.S. five-year relative survival by SEER stage, eye melanoma diagnosed 2015 to 2021; Estimated U.S. deaths in 2026, all eye and orbit cancer; 17 further topics. 21 evidence topics quoted from 19 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Five-year relative survival, all uveal melanoma, 1975 to 2016

> “The 5-year relative survival rate (82.8%) remained stable during the period from 1975 to 2016 (5-year follow-up data are not yet available for 2017–2020)”

Source: [Weinberger et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11991740/)

<a id="topic-2.2.1.3-2"></a>

### Five-year and ten-year relative survival, all uveal melanoma

> “5- and 10-year relative survival rates were 83.3% and 73.9%, respectively, with worse outcomes in metastatic disease.”

Source: [Alfaar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40936061/)

<a id="topic-2.2.1.3-3"></a>

### U.S. five-year relative survival by SEER stage, eye melanoma diagnosed 2015 to 2021

> “These numbers are based on people diagnosed with melanoma of the eye (also known as ocular melanoma or intraocular melanoma) between 2015 and 2021.”

Source: [American Cancer Society eye cancer survival rates (2025)](https://www.cancer.org/cancer/types/eye-cancer/detection-diagnosis-staging/survival-rates.html)

| SEER stage, eye melanoma | 5-year relative survival rate |
| --- | --- |
| Localized | “88%” |
| Regional | “65%” |
| Distant | “19%” |
| All SEER stages combined | “84%” |

Source: [American Cancer Society eye cancer survival rates (2025)](https://www.cancer.org/cancer/types/eye-cancer/detection-diagnosis-staging/survival-rates.html)

<a id="topic-2.2.1.3-4"></a>

### Estimated U.S. deaths in 2026, all eye and orbit cancer

| Site, United States, 2026 | Estimated deaths, both sexes | Male | Female |
| --- | --- | --- | --- |
| Eye and orbit | “530” | “280” | “250” |

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)

<a id="topic-2.2.1.3-5"></a>

### Long-term metastasis-free survival and melanoma-related death

> “The KM estimates of MFS were 0.729 (0.719, 0.74), 0.648 (0.633, 0.663), and 0.616 (0.596, 0.636) at 10, 20, and 30 years, respectively. The cumulative probabilities of melanoma metastatic death at 10, 20 and 30 years were 0.241 (0.236, 0.245), 0.289 (0.283, 0.294), and 0.301 (0.295, 0.307).”
> “Death due to melanoma were rare beyond 20 years with normal life expectancy reached at 25 years after primary therapy.”

Source: [Radivoyevitch et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8130945/)

<a id="topic-2.2.1.3-6"></a>

### Uveal melanoma-related mortality over 35 years and late metastatic death

> “Uveal melanoma-related mortality was 31% (95% confidence interval [CI], 26-37) by 5 years, 45% (95% CI, 40-51) by 15 years, 49% (95% CI, 43-55) by 25 years, and 52% (95% CI, 45-58) by 35 years, according to cumulative incidence analysis.”
> “Of patients who died of uveal melanoma, 62%, 90%, 98%, and 100% did so within 5, 15, 25, and 35 years, respectively.”

Source: [Kujala et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/14578381/)

<a id="topic-2.2.1.3-7"></a>

### Time from treatment of the primary tumor to metastasis

> “The median time from the initial treatment of the tumor to metastasis was 3.45 years (interquartile range [IQR], 2.0-5.57).”

Source: [Lane et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6142974/)

<a id="topic-2.2.1.3-8"></a>

### Micrometastatic dormancy and late liver metastasis

> “Metastatic liver disease is the overwhelming cause of death in uveal melanoma patients, with almost 50% of patients developing liver metastases up to 15 years after diagnosis.”
> “Most of these patients do not present with any evidence of overt metastasis at the time of initial diagnosis although it is assumed that they have undetectable micrometastases.”

Source: [Bakalian et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18281525/)

<a id="topic-2.2.1.3-9"></a>

### Prognosis after extraocular extension, recurrence, or metastasis

> “Extraocular extension, recurrence, and metastasis are associated with an extremely poor prognosis, and long-term survival cannot be expected for patients with these features.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.1.3-10"></a>

### Course after metastasis: liver involvement, survival beyond 5 years, and cure rate

> “Almost 50% of patients develop metastatic disease, which usually involves the liver, and is usually fatal within 1 year.”

Source: [Jager et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32273508/)

> “Meta-analyses confirm a median overall survival of 10-13 months, and a cure rate that approaches nil, although survival exceeding 5 years is possible, estimated 2% either with first-line treatment or with best supportive care.”

Source: [Rantala et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34999237/)

<a id="topic-2.2.1.3-11"></a>

### Death rate after diagnosis of metastasis, COMS trials

> “The death rate following the report of melanoma metastasis was 80% at 1 year (95% confidence interval, 77%-83%) and 92% at 2 years (95% confidence interval, 89%-94%).”
> “Long-term survival after diagnosis of metastasis was uncommon; only 8 patients survived 5 or more years.”

Source: [Diener-West et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16344433/)

<a id="topic-2.2.1.3-12"></a>

### Survival after diagnosis of metastasis with and without treatment

> “Overall, the median survival time was poor (3.9 months [IQR, 1.6-10.1]). Patients who received treatment fared better than those who did not receive treatment (median survival after metastasis diagnosis, 6.3 months [IQR, 2.96-14.41] vs 1.7 months [IQR, 0.66-3.5]).”

Source: [Lane et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6142974/)

<a id="topic-2.2.1.3-13"></a>

### Pooled overall survival after metastasis, meta-analysis of 78 articles with 2494 participants

> “Individual-level data were obtained from 78 articles with 2494 patients. The median OS across all treatment modalities was 1.07 years (range: 0.59–2.50 years).”
> “Reported OS was unassociated with the decade of publication, but depended on the percentage of first-line treated patients.”

Source: [Rantala et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6887637/)

<a id="topic-2.2.1.3-14"></a>

### Progression-free and overall survival benchmarks

> “The median PFS was 3.3 months (95% CI 2.9-3.6) and 6-month PFS rate was 27% (95% CI 24-30).”
> “The median OS was 10.2 months (95% CI 9.5-11.0) and 1 year OS was 43% (95% CI 40-47).”

Source: [Khoja et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31150059/)

<a id="topic-2.2.1.3-15"></a>

### One-year survival in a cohort with metastatic uveal melanoma

> “In our cohort, one-year survival for all patients with metastatic uveal melanoma is equal to 47.8% (95% CI 40.4–55.2), similar to that reported in known publications”

Source: [Jochems et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6678641/)

<a id="topic-2.2.1.3-16"></a>

### Overall survival with active treatment by working formulation stage

> “The median OS with active treatment was 18 (range, 0.7–162), 6.9 (range, 1.3–30) and 1.9 (range, 0.2–18) months in working formulation stage IVa, IVb and IVc, respectively.”

Source: [Rantala et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8081447/)

<a id="topic-2.2.1.3-17"></a>

### Prognostic factors after metastasis: lactate dehydrogenase, alkaline phosphatase, and liver metastasis size

> “Univariable analysis showed male sex, elevated (i.e. > versus ≤ upper limit of normal) lactate dehydrogenase (LDH), elevated alkaline phosphatase (ALP) and diameter of the largest liver metastasis (≥3 cm versus <3 cm) to be substantially associated with shorter PFS.”
> “The most substantial prognostic factors for shorter OS by univariable and multivariable analysis were elevated LDH and elevated ALP.”

Source: [Khoja et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31150059/)

> “The multivariable Cox analysis showed that slight to moderately elevated LDH (250–500 U/L) and high LDH level (>500 U/L) were a statistically significant factor associated with poor survival (p < 0.001), HR of 1.8 (95% CI 1.07–3.01) and 9.0 (95% CI 5.63–14.35) respectively. Also, the presence of liver metastases was negatively associated with survival, HR 2.09 (95% CI 1.07–4.08, p = 0.03).”

Source: [Jochems et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6678641/)

> “Different staging systems predict survival after metastatic disease appears, based on tumour burden, liver function tests, World Health Organization performance status (PS) and metastasis-free interval.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.3-18"></a>

### AJCC distant metastasis categories by largest metastasis diameter

| AJCC M category | Definition |
| --- | --- |
| M1a | “Largest diameter of the largest metastasis ≤3.0 cm.” |
| M1b | “Largest diameter of the largest metastasis 3.1–8.0 cm.” |
| M1c | “Largest diameter of the largest metastasis ≥8.1 cm.” |

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.1.3-19"></a>

### Distribution of AJCC M categories in a nationwide Finnish cohort

> “The largest metastasis was small (M1a) in 52%, medium-sized (M1b) in 31%, large (M1c) in 11%, and undetermined in 6% of patients.”

Source: [Rantala et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8081447/)

<a id="topic-2.2.1.3-20"></a>

### Survival by mode of detection of metastasis

> “Cumulative rates of melanoma-related death were higher for patients in the symptomatic group vs the asymptomatic group (P < .001, log-rank test) owing to differences in mortality observed in the first year after diagnosis of metastasis (87.8% vs 68.5%).”
> “Presymptomatic detection of metastatic uveal melanoma by routine surveillance testing seems to confer a survival advantage only in the first year after diagnosis of metastasis, which is likely because of lead-time bias.”

Source: [Kim et al. (2010)](https://jamanetwork.com/journals/jamaophthalmology/fullarticle/425938)

> “However, with multivariable analysis, the only variable that remained a significant risk of mortality was diagnosis by symptoms (HR 2.39 p < 0.017).”

Source: [Xu et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6751472/)

<a id="topic-2.2.1.3-21"></a>

### Delay before the effect of newer systemic therapies appears in SEER data

> “It will be several years before impact of newer systemic therapies for uveal melanoma is captured in SEER database”

Source: [Weinberger et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11991740/)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
